Conjunctivitis News and Research

RSS

Conjunctivitis is an eye infection that may cause redness and discharge from the eye, sometimes with pain or itching. It can be caused by bacteria or viruses.

FDA approves ivermectin lotion for treatment of head lice

Sanofi announced today that the U.S. Food and Drug Administration (FDA) has approved Sklice® (ivermectin) lotion, 0.5% for the topical treatment of head lice, in patients 6 months of age and older. Effective and well-tolerated, Sklice Lotion treats lice in most patients with a single 10-minute application of the lotion, without nit combing.

7 Feb 2012

No link between availability of primary care physician and retail clinic use

Use of retail medical clinics located in pharmacies and other retail settings increased 10-fold between 2007 and 2009, according to a new RAND Corporation study.

23 Nov 2011

Perrigo's partner receives final approval for Epinastine HCl ophthalmic solution

Perrigo Company today announced that its partner, PharmaForce/Luitpold Pharmaceuticals, received final approval for Epinastine HCl ophthalmic solution, 0.05%, a generic version of Elestat. Perrigo will commence shipment of the product immediately.

2 Nov 2011

HAL Allergy initiates PURETHAL Mites PHASE II study

HAL Allergy B.V. today announced that it has included the first patient in its PHASE II dose range finding study.

31 Oct 2011

Gilead, Bristol-Myers Squibb to develop and commercialize fixed-dose combination for HIV

Bristol-Myers Squibb Company and Gilead Sciences, Inc. today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor REYATAZ (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.

27 Oct 2011

Janssen announces FDA label update approval for PREZISTA HIV tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for PREZISTA (darunavir) tablets to include 192-week data from the ARTEMIS study.

22 Oct 2011

New collaboration reinforces Sanofi's translational discovery platform for retinal diseases

The Max Planck Society (Max-Planck-Gesellschaft), Germany's leading basic research organization, announced today that it has signed with Fovea Pharmaceuticals, the Ophthalmology Division of Sanofi, a research collaboration and license agreement to identify and develop innovative solutions for restoring vision in patients suffering from diseases affecting the retina.

16 Sep 2011

NIH awards Rutgers and UMDNJ $23.2M grant to develop drugs against mustard gas

The National Institutes of Health (NIH) has awarded a five-year $23.2 million grant to a group of investigators at Rutgers University and the University of Medicine and Dentistry of New Jersey (UMDNJ)-Robert Wood Johnson Medical School to continue their research aimed at developing drug products that could be used against chemical warfare agents from a terrorist attack.

14 Sep 2011

IOM report: Few health problems are clearly associated with vaccines

An analysis of more than 1,000 research articles concluded that few health problems are caused by or clearly associated with vaccines.

26 Aug 2011

Infectious adenoviruses and noroviruses in bathing water could pose a risk to health

European researchers have found viruses in nearly 40% of more than 1,400 bathing water samples gathered from coastal and inland areas in nine countries, including Spain. The concentrations found are low, but the scientists are calling for these microorganisms to be monitored in recreational waters, above all at times when their populations skyrocket, as is the case after heavy rains.

8 Jul 2011

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent.

28 Jun 2011

Meda presents new positive results from Dymista Phase-III trial on AR at EAACI 2011

Meda presents new positive results from a Phase-III clinical trial of Dymista at the annual meeting of the European Academy of Allergy and Clinical Immunology (EAACI) in Istanbul, Turkey.

15 Jun 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Bristol-Myers Squibb Company announced today it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.

4 Jun 2011

YM announces updates on nimotuzumab clinical development program

YM BioSciences Inc., today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for nimotuzumab at the 2011 Annual Meeting of the American Society of Clinical Oncology.

31 May 2011

Largest number of measles cases in the US since 1996: Report

According to the latest report from the Centers for Disease Control and Prevention (CDC), the United States has had 118 measles cases so far this year, the most for this date since 1996, and close to 90% of them are linked to cases in other countries.

24 May 2011

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver).

23 May 2011

Inspire reports net loss of $17.6 million for first quarter 2011

Inspire Pharmaceuticals, Inc. announced today financial results for the first quarter ended March 31, 2011, reporting a net loss of $17.6 million or per common share, as compared to a net loss of $14.8 million, or per common share, for the same period in 2010.

10 May 2011

Merck, Inspire announce expiration of HSR waiting period for cash tender offer

Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR") has expired in connection with the previously announced cash tender offer made by Monarch Transaction Corp., a wholly owned subsidiary of Merck, to purchase all of the outstanding shares of common stock of Inspire.

28 Apr 2011

WSU researcher develops potential vaccine for Chlamydia

A Wayne State University School of Medicine researcher has developed a potential first ever vaccine for Chlamydia, the world's most prevalent sexually transmitted disease and the leading cause of new cases of blindness.

21 Apr 2011